Zion Pharma inks agreement with Roche to develop and commercialize brain-penetrable compounds
ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer